Chang, J. T. Pathophysiology of Inflammatory Bowel Diseases. N. Engl. J. Med. 383, 2652–2664 (2020).

Article  CAS  PubMed  Google Scholar 

Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 160, 1570–1583 (2021).

Article  CAS  PubMed  Google Scholar 

Le Berre, C. et al. Selecting end points for disease-modification trials in inflammatory bowel disease: the SPIRIT consensus from the IOIBD. Gastroenterology 160, 1452–1460 (2021).

Article  PubMed  Google Scholar 

Le Berre, C., Honap, S. & Peyrin-Biroulet, L. Ulcerative colitis. Lancet 402, 571–584 (2023).

Article  PubMed  Google Scholar 

Dolinger, M., Torres, J. & Vermeire, S. Crohn’s disease. Lancet 403, 1177–1191 (2024).

Article  CAS  PubMed  Google Scholar 

Raine, T. & Danese, S. Breaking through the therapeutic ceiling: what will it take? Gastroenterology 162, 1507–1511 (2022).

Article  PubMed  Google Scholar 

Alsoud, D., Verstockt, B., Fiocchi, C. & Vermeire, S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol. Hepatol. 6, 589–595 (2021).

Article  PubMed  Google Scholar 

Magro, F. et al. Has the therapeutical ceiling been reached in Crohn’s disease randomized controlled trials? A systematic review and meta-analysis. United European Gastroenterol. J. 11, 202–217 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Bemelman, W. A. et al. Evolving role of IBD surgery. J. Crohns Colitis 12, 1005–1007 (2018).

Article  CAS  PubMed  Google Scholar 

Villablanca, E. J., Selin, K. & Hedin, C. R. H. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression? Nat. Rev. Gastroenterol. Hepatol. 19, 493–507 (2022).

Article  PubMed  Google Scholar 

Svartz, N. Salazopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic effects in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparations. Acta Med. Scand. 110, 580–598 (1942).

Article  Google Scholar 

Svartz, N. The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa. Acta Med. Scand. 130, 465–472 (1948).

Article  Google Scholar 

Azad Khan, A. K., Piris, J. & Truelove, S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2, 892–895 (1977).

Article  CAS  PubMed  Google Scholar 

Truelove, S. C. W. L. Cortisone in ulcerative colitis final report on a therapeutic trial. Br. Med. J. 2, 1041–1048 (1955).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bean, R. H. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med. J. Aust. 49, 592–593 (1962).

Article  Google Scholar 

Bean, R. H. D. Treatment of ulcerative colitis with antimetabolites. Br. Med. J. 1, 1081–1084 (1966).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jewell, D. P. & Truelove, S. C. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br. Med. J. 4, 627–630 (1974).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mulder, D. J., Noble, A. J., Justinich, C. J. & Duffin, J. M. A tale of two diseases: the history of inflammatory bowel disease. J. Crohns Colitis 8, 341–348 (2014).

Article  PubMed  Google Scholar 

United States Food and Drug Administration. Product approval for infliximab (FDA, 1998).

Hanauer, S. B. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130, 323–333 (2006).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 56, 1232–1239 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60, 780–787 (2011).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 142, 257–265 (2012).

Article  CAS  PubMed  Google Scholar 

Reinisch, W. et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm. Bowel Dis. 19, 1700–1709 (2013).

Article  PubMed  Google Scholar 

Sandborn, W. J. et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med. 357, 228–238 (2007).

Article  CAS  PubMed  Google Scholar 

Schreiber, S. et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med. 357, 239–250 (2007).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 146, 96–109 (2014).

Article  CAS  PubMed  Google Scholar 

Rutgeerts, P. et al. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment. Pharmacol. Ther. 42, 504–514 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).

Article  CAS  PubMed  Google Scholar 

Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 369, 711–721 (2013).

Article  CAS  PubMed  Google Scholar 

Feagan, B. G. et al. Ustekinumab as Induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 375, 1946–1960 (2016).

Article  CAS  PubMed  Google Scholar 

Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201–1214 (2019).

Article  CAS  PubMed  Google Scholar 

D’Haens, G. et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 399, 2015–2030 (2022).

Article  PubMed  Google Scholar 

Ferrante, M. et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 399, 2031–2046 (2022).

Article  CAS  PubMed